Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy

Int J Tuberc Lung Dis. 2011 Apr;15(4):547-50. doi: 10.5588/ijtld.10.0140.


We describe the efficacy and outcome of standardised second-line anti-tuberculosis (TB) medications during pregnancy. Treatment outcomes of five pregnant women with documented multidrug-resistant TB (MDR-TB) referred to the National Research Institute of Tuberculosis and Lung Diseases from 2003 to 2009 were analysed in two categories, maternal and neonatal. Patients became pregnant during treatment for MDR-TB without any changes in their anti-tuberculosis regimen. None of them had any adverse effects during pregnancy and delivery. No adverse effects were observed in mothers or neonates. The treatment of MDR-TB during pregnancy with a standardised second-line regimen in this study population was safe, with an acceptable rate of treatment success.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / therapeutic use*
  • Female
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / microbiology
  • Pregnancy Outcome
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Young Adult


  • Antitubercular Agents